{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T03:00:28Z","timestamp":1773802828794,"version":"3.50.1"},"reference-count":170,"publisher":"Bentham Science Publishers Ltd.","issue":"8","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CDT"],"published-print":{"date-parts":[[2019,5,10]]},"abstract":"<jats:sec><jats:title\/><jats:p>Fibroblast growth factors (FGFs) are pleiotropic molecules exerting autocrine, intracrine and paracrine functions via activating four tyrosine kinase FGF receptors (FGFR), which further trigger a variety of cellular processes including angiogenesis, evasion from apoptosis, bone formation, embryogenesis, wound repair and homeostasis. Four major mechanisms including angiogenesis, inflammation, cell proliferation, and metastasis are active in FGF\/FGFR-driven tumors. Furthermore, gain-of-function or loss-of-function in FGFRs1-4 which is due to amplification, fusions, mutations, and changes in tumor\u2013stromal cells interactions, is associated with the development and progression of cancer. Although, the developed small molecule or antibodies targeting FGFR signaling offer immense potential for cancer therapy, emergence of drug resistance, activation of compensatory pathways and systemic toxicity of modulators are bottlenecks in clinical application of anti-FGFRs. In this review, we present FGF\/FGFR structure and the mechanisms of its function, as well as cross-talks with other nodes and\/or signaling pathways. We describe deregulation of FGF\/FGFR-related mechanisms in human disease and tumor progression leading to the presentation of emerging therapeutic approaches, resistance to FGFR targeting, and clinical potentials of individual FGF family in several human cancers. Additionally, the underlying biological mechanisms of FGF\/FGFR signaling, besides several attempts to develop predictive biomarkers and combination therapies for different cancers have been explored.<\/jats:p><\/jats:sec>","DOI":"10.2174\/1389450120666190112145409","type":"journal-article","created":{"date-parts":[[2019,1,16]],"date-time":"2019-01-16T11:22:41Z","timestamp":1547637761000},"page":"852-870","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Implications of Fibroblast Growth Factors (FGFs) in Cancer: From Prognostic to Therapeutic Applications"],"prefix":"10.2174","volume":"20","author":[{"given":"Hassan","family":"Dianat-Moghadam","sequence":"first","affiliation":[{"name":"Molecular Medicine Department, Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ladan","family":"Teimoori-Toolabi","sequence":"additional","affiliation":[{"name":"Molecular Medicine Department, Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1248\/bpb.b14-00265","volume":"37","author":"Imamura T.","year":"2014","unstructured":"Imamura T. Biol Pharm Bull, Physiological functions and underlying mechanisms of fibroblast growth factor (FGF) family members: Recent findings and implications for their pharmacological application.,, 2014, 37,, 1081-1089,","journal-title":"Biol Pharm Bull"},{"key":"ref=2","doi-asserted-by":"crossref","first-page":"41","DOI":"10.4103\/0976-433X.149592","volume":"6","author":"Dey D.","year":"2015","unstructured":"Dey D, Nandhini G, Rajkumar K. SRM J Res Dental Sci, Fibroblast growth factors and their role in disease and therapy.,, 2015, 6,, 41-,","journal-title":"SRM J Res Dental Sci"},{"key":"ref=3","first-page":"18","volume":"5","author":"Ohta H.","year":"2013","unstructured":"Ohta H, Itoh N. Front Endocrinol, Roles of FGFs as adipokines in adipose tissue development, remodeling, and metabolism.,, 2013, 5,, 18-,","journal-title":"Front Endocrinol"},{"key":"ref=4","doi-asserted-by":"crossref","first-page":"729352","DOI":"10.1155\/2015\/729352","volume":"2015","author":"Takei Y.","year":"2015","unstructured":"Takei Y, Minamizaki T, Yoshiko Y. Int J Endocrinol, Functional diversity of fibroblast growth factors in bone formation.,, 2015, 2015,, 729352-,","journal-title":"Int J Endocrinol"},{"key":"ref=5","author":"Raju R","year":"","unstructured":"Raju R, Palapetta SM, Sandhya VK. , , A network map of FGF- 1\/FGFR signaling system. J Signal Transduction 2014; 2014.,"},{"key":"ref=6","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1006\/dbio.1993.1205","volume":"158","author":"Orr-Urtreger A.","year":"1993","unstructured":"Orr-Urtreger A, Bedford MT, Burakova T. Dev Biol, Developmental localization of the splicing alternatives of fibroblast growth factor receptor-2 (FGFR2).,, 1993, 158,, 475-486,","journal-title":"Dev Biol"},{"key":"ref=7","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1002\/med.21288","volume":"34","author":"Katoh M.","year":"2014","unstructured":"Katoh M, Nakagama H. Med Res Rev, FGF receptors: cancer biology and therapeutics.,, 2014, 34,, 280-300,","journal-title":"Med Res Rev"},{"key":"ref=8","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.pharmthera.2017.05.013","volume":"179","author":"Presta M.","year":"2017","unstructured":"Presta M, Chiodelli P, Giacomini A, Rusnati M, Ronca R. Pharmacol Ther, Fibroblast growth factors (FGFs) in cancer: FGF traps as a new therapeutic approach.,, 2017, 179,, 171-187,","journal-title":"Pharmacol Ther"},{"key":"ref=9","doi-asserted-by":"crossref","first-page":"3417","DOI":"10.1128\/MCB.02249-06","volume":"27","author":"Goetz R.","year":"2007","unstructured":"Goetz R, Beenken A, Ibrahimi OA. Mol Cell Biol, Molecular insights into the klotho-dependent, endocrine mode of action of fibroblast growth factor 19 subfamily members.,, 2007, 27,, 3417-3428,","journal-title":"Mol Cell Biol"},{"key":"ref=10","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.bbagen.2008.09.001","volume":"1790","author":"Asada M.","year":"2009","unstructured":"Asada M, Shinomiya M, Suzuki M. General Subjects, Glycosaminoglycan affinity of the complete fibroblast growth factor family. Biochimica et Biophysica Acta (BBA)-.,, 2009, 1790,, 40-48,","journal-title":"General Subjects"},{"key":"ref=11","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.mce.2008.10.052","volume":"299","author":"Kurosu H.","year":"2009","unstructured":"Kurosu H, Kuro-o M. Mol Cell Endocrinol, The Klotho gene family as a regulator of endocrine fibroblast growth factors.,, 2009, 299,, 72-78,","journal-title":"Mol Cell Endocrinol"},{"key":"ref=12","doi-asserted-by":"crossref","first-page":"26687","DOI":"10.1074\/jbc.M704165200","volume":"282","author":"Kurosu H.","year":"2007","unstructured":"Kurosu H, Choi M, Ogawa Y. J Biol Chem, Tissue-specific expression of \u03b2Klotho and fibroblast growth factor (FGF) receptor isoforms determines metabolic activity of FGF19 and FGF21.,, 2007, 282,, 26687-26695,","journal-title":"J Biol Chem"},{"key":"ref=13","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1021\/jm051106d","volume":"49","author":"Bhide R.S.","year":"2006","unstructured":"Bhide RS, Cai Z-W, Zhang Y-Z. J Med Chem, Discovery and preclinical studies of (R)-1-(4-(4-Fluoro-2-methyl-1 H-indol-5-yloxy)-5-methylpyrrolo [2, 1-f][1, 2, 4] triazin-6-yloxy) propan-2-ol (BMS-540215), an in vivo active potent VEGFR-2 inhibitor.,, 2006, 49,, 2143-2146,","journal-title":"J Med Chem"},{"key":"ref=14","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/cr.2008.302","volume":"19","author":"Guo X.","year":"2009","unstructured":"Guo X, Wang X-F. Cell Res, Signaling cross-talk between TGF-\u03b2\/BMP and other pathways.,, 2009, 19,, 71-88,","journal-title":"Cell Res"},{"key":"ref=15","author":"Pownall M.E.","unstructured":"Pownall ME, Isaacs HV, , ,, , Colloquium Series Dev Biol 2010: Morgan & Claypool Life Sciences;, FGF signalling in vertebrate development. Colloquium Series Dev Biol., ,-","journal-title":"FGF signalling in vertebrate development Colloquium Series Dev Biol"},{"key":"ref=16","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/j.ygyno.2013.09.034","volume":"131","author":"Arend R.C.","year":"2013","unstructured":"Arend RC, Londo\u00f1o-Joshi AI, Straughn JM, Buchsbaum DJ. Gynecol Oncol, The Wnt\/\u03b2-catenin pathway in ovarian cancer: A review.,, 2013, 131,, 772-779,","journal-title":"Gynecol Oncol"},{"key":"ref=17","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1373\/clinchem.2013.211490","volume":"60","author":"Meng Q.H.","year":"2014","unstructured":"Meng QH, Xu E, Hildebrandt MA. Clin Chem, Genetic variants in the fibroblast growth factor pathway as potential markers of ovarian cancer risk, therapeutic response, and clinical outcome.,, 2014, 60,, 222-232,","journal-title":"Clin Chem"},{"key":"ref=18","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0925-4773(97)00160-3","volume":"69","author":"McGrew L.L.","year":"1997","unstructured":"McGrew LL, Hoppler S, Moon RT. Mech Dev, Wnt and FGF pathways cooperatively pattern anteroposterior neural ectoderm in Xenopus.,, 1997, 69,, 105-114,","journal-title":"Mech Dev"},{"key":"ref=19","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.4161\/cbt.5.9.3151","volume":"5","author":"Kotoh M.","year":"2006","unstructured":"Kotoh M, Katoh M. Cancer Biol Ther, Cross-talk of WNT and FGF signaling pathways at GSK3\u03b2 to regulate \u03b2-catenin and SNAIL signaling cascades.,, 2006, 5,, 1059-1064,","journal-title":"Cancer Biol Ther"},{"key":"ref=20","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1242\/dev.099507","volume":"141","author":"Dyer C.","year":"2014","unstructured":"Dyer C, Blanc E, Hanisch A. Development, A bi-modal function of Wnt signalling directs an FGF activity gradient to spatially regulate neuronal differentiation in the midbrain.,, 2014, 141,, 63-72,","journal-title":"Development"},{"key":"ref=21","doi-asserted-by":"crossref","first-page":"2728","DOI":"10.2337\/db07-1252","volume":"57","author":"Lovis P.","year":"2008","unstructured":"Lovis P, Roggli E, Laybutt DR. Diabetes, Alterations in microRNA expression contribute to fatty acid-induced pancreatic \u03b2-cell dysfunction.,, 2008, 57,, 2728-2736,","journal-title":"Diabetes"},{"key":"ref=22","author":"Lin W-h","year":"","unstructured":"Lin W-h, Xiang L-J, Shi H-X. , , Fibroblast growth factors stimulate hair growth through \u03b2-catenin and Shh expression in C57BL\/6 mice. BioMed Res Int 2015; 2015.,"},{"key":"ref=23","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1159\/000066755","volume":"66","author":"Kolligs F.T.","year":"2002","unstructured":"Kolligs FT, Bommer G, G\u00f6ke B. Digestion, Wnt\/beta-catenin\/tcf signaling: A critical pathway in gastrointestinal tumorigenesis.,, 2002, 66,, 131-144,","journal-title":"Digestion"},{"key":"ref=24","first-page":"6116","volume":"63","author":"Shimokawa T.","year":"2003","unstructured":"Shimokawa T, Furukawa Y, Sakai M. Cancer Res, Involvement of the FGF18 gene in colorectal carcinogenesis, as a novel downstream target of the \u03b2-catenin\/T-cell factor complex.,, 2003, 63,, 6116-6120,","journal-title":"Cancer Res"},{"key":"ref=25","first-page":"142","volume":"11","author":"Teimoori-Toolabi L.","year":"2009","unstructured":"Teimoori-Toolabi L, Azadmanesh K, Jamali S. Yakhteh Med J, Studying the activity of fibroblast growth factor 18 and urokinase plasminogen activator receptor promoters in two colon cancer cell lines.,, 2009, 11,, 142-153,","journal-title":"Yakhteh Med J"},{"key":"ref=26","doi-asserted-by":"crossref","first-page":"131","DOI":"10.2165\/11530840-000000000-00000","volume":"24","author":"Teimoori-Toolabi L.","year":"2010","unstructured":"Teimoori-Toolabi L, Azadmanesh K, Amanzadeh A, Zeinali S. BioDrugs, Selective suicide gene therapy of colon cancer exploiting the urokinase plasminogen activator receptor promoter.,, 2010, 24,, 131-146,","journal-title":"BioDrugs"},{"key":"ref=27","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1089\/cbr.2009.0643","volume":"25","author":"Teimoori-Toolabi L.","year":"2010","unstructured":"Teimoori-Toolabi L, Azadmanesh K, Zeinali S. Cancer Biother Radiopharm, Selective suicide gene therapy of colon cancer cell lines exploiting fibroblast growth factor 18 promoter.,, 2010, 25,, 105-116,","journal-title":"Cancer Biother Radiopharm"},{"key":"ref=28","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/nrc2780","volume":"10","author":"Turner N.","year":"2010","unstructured":"Turner N, Grose R. Nat Rev Cancer, Fibroblast growth factor signalling: From development to cancer.,, 2010, 10,, 116-129,","journal-title":"Nat Rev Cancer"},{"key":"ref=29","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.gendis.2014.09.005","volume":"1","author":"Teven C.M.","year":"2014","unstructured":"Teven CM, Farina EM, Rivas J, Reid RR. Genes Dis, Fibroblast growth factor (FGF) signaling in development and skeletal diseases.,, 2014, 1,, 199-213,","journal-title":"Genes Dis"},{"key":"ref=30","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.3345\/kjp.2010.53.12.1022","volume":"53","author":"Noe E.J.","year":"2010","unstructured":"Noe EJ, Yoo HW, Kim KN, Lee SY. Korean J Pediatr, A case of thanatophoric dysplasia type I with an R248C mutation in the FGFR3 gene.,, 2010, 53,, 1022-1025,","journal-title":"Korean J Pediatr"},{"key":"ref=31","author":"Schaefer E","year":"","unstructured":"Schaefer E, Minoux M, Lauer J. , , A novel mutation involving the initiation codon of fgf3 in a family described with complete inner ear agenesis, microtia and major microdontia (LAMM Syndrome). J Genetic Syndromes Gene Ther 2014; 2014.,"},{"key":"ref=32","doi-asserted-by":"crossref","first-page":"e60439","DOI":"10.1371\/journal.pone.0060439","volume":"8","author":"Yeh E.","year":"2013","unstructured":"Yeh E, Fanganiello RD, Sunaga DY. PLoS One, Novel molecular pathways elicited by mutant FGFR2 may account for brain abnormalities in Apert syndrome.,, 2013, 8,, e60439-,","journal-title":"PLoS One"},{"key":"ref=33","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1111\/j.1469-7580.2012.01555.x","volume":"221","author":"Percival C.J.","year":"2012","unstructured":"Percival CJ, Wang Y, Zhou X, Jabs EW, Richtsmeier JT. J Anat, The effect of a Beare\u2010Stevenson syndrome Fgfr2 Y394C mutation on early craniofacial bone volume and relative bone mineral density in mice.,, 2012, 221,, 434-442,","journal-title":"J Anat"},{"key":"ref=34","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s004390050979","volume":"104","author":"Cornejo-Roldan L.R.","year":"1999","unstructured":"Cornejo-Roldan LR, Roessler E, Muenke M. Hum Genet, Analysis of the mutational spectrum of the FGFR2 gene in Pfeiffer syndrome.,, 1999, 104,, 425-431,","journal-title":"Hum Genet"},{"key":"ref=35","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1038\/nature07385","volume":"455","author":"McLendon R.","year":"2008","unstructured":"McLendon R, Friedman A, Bigner D. Nature, Comprehensive genomic characterization defines human glioblastoma genes and core pathways.,, 2008, 455,, 1061-1068,","journal-title":"Nature"},{"key":"ref=36","author":"Weiss J","year":"","unstructured":"Weiss J, Sos ML, Seidel D. Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer., , Sci Translational Med 2010; 2(62): 62ra93-62ra93.,","journal-title":"Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer"},{"key":"ref=37","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1158\/0008-5472.CAN-09-3746","volume":"70","author":"Turner N.","year":"2010","unstructured":"Turner N, Pearson A, Sharpe R. Cancer Res, FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer.,, 2010, 70,, 2085-2094,","journal-title":"Cancer Res"},{"key":"ref=38","doi-asserted-by":"crossref","first-page":"e0122961","DOI":"10.1371\/journal.pone.0122961","volume":"10","author":"Sheu M-J.","year":"2015","unstructured":"Sheu M-J, Hsieh M-J, Chiang W-L. PLoS One, Fibroblast growth factor receptor 4 polymorphism is associated with liver cirrhosis in hepatocarcinoma.,, 2015, 10,, e0122961-,","journal-title":"PLoS One"},{"key":"ref=39","doi-asserted-by":"crossref","first-page":"e1046","DOI":"10.1038\/cddis.2014.10","volume":"5","author":"Turkington R.","year":"2014","unstructured":"Turkington R, Longley D, Allen W. Cell Death Dis, Fibroblast growth factor receptor 4 (FGFR4): A targetable regulator of drug resistance in colorectal cancer.,, 2014, 5,, e1046-,","journal-title":"Cell Death Dis"},{"key":"ref=40","doi-asserted-by":"crossref","first-page":"3422","DOI":"10.1158\/1538-7445.AM2014-3422","volume":"74","author":"Azorsa D.O.","year":"2014","unstructured":"Azorsa DO, Gonzales IM, Arora S. Cancer Res, RNAi screening identifies FGFR4 as a modulator of growth and survival in Ewing sarcoma.,, 2014, 74,, 3422-,","journal-title":"Cancer Res"},{"key":"ref=41","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1093\/hmg\/dds486","volume":"22","author":"Williams S.V.","year":"2013","unstructured":"Williams SV, Hurst CD, Knowles MA. Hum Mol Genet, Oncogenic FGFR3 gene fusions in bladder cancer.,, 2013, 22,, 795-803,","journal-title":"Hum Mol Genet"},{"key":"ref=42","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1158\/2159-8290.CD-13-0050","volume":"3","author":"Wu Y-M.","year":"2013","unstructured":"Wu Y-M, Su F, Kalyana-Sundaram S. Cancer Discov, Identification of targetable FGFR gene fusions in diverse cancers.,, 2013, 3,, 636-647,","journal-title":"Cancer Discov"},{"key":"ref=43","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1038\/nrc.2017.8","volume":"17","author":"Babina I.S.","year":"2017","unstructured":"Babina IS, Turner NC. Nat Rev Cancer, Advances and challenges in targeting FGFR signalling in cancer.,, 2017, 17,, 318-,","journal-title":"Nat Rev Cancer"},{"key":"ref=44","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1158\/1535-7163.MCT-14-0927-T","volume":"14","author":"Nakanishi Y.","year":"2015","unstructured":"Nakanishi Y, Akiyama N, Tsukaguchi T. Mol Cancer Ther, Mechanism of oncogenic signal activation by the novel fusion kinase FGFR3-BAIAP2L1.,, 2015, 14,, 704-712,","journal-title":"Mol Cancer Ther"},{"key":"ref=45","doi-asserted-by":"crossref","first-page":"3307","DOI":"10.1158\/1078-0432.CCR-14-2199","volume":"21","author":"Di Stefano A.L.","year":"2015","unstructured":"Di Stefano AL, Fucci A, Frattini V. Clin Cancer Res, Detection, characterization, and inhibition of FGFR\u2013TACC fusions in IDH wild-type glioma.,, 2015, 21,, 3307-3317,","journal-title":"Clin Cancer Res"},{"key":"ref=46","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/nature12965","volume":"507","author":"Network C.G.A.R.","year":"2014","unstructured":"Network CGAR. Nature, Comprehensive molecular characterization of urothelial bladder carcinoma.,, 2014, 507,, 315-322,","journal-title":"Nature"},{"key":"ref=47","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1002\/path.4209","volume":"230","author":"Majewski I.J.","year":"2013","unstructured":"Majewski IJ, Mittempergher L, Davidson NM. J Pathol, Identification of recurrent FGFR3 fusion genes in lung cancer through kinome\u2010centred RNA sequencing.,, 2013, 230,, 270-276,","journal-title":"J Pathol"},{"key":"ref=48","author":"Parker BC","year":"","unstructured":"Parker BC, Annala MJ, Cogdell DE. , , The tumorigenic FGFR3-TACC3 gene fusion escapes miR-99a regulation in glioblastoma. J Clin Investigation 2013;123(2): 0.,"},{"key":"ref=49","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1472-6750-14-1","volume":"14","author":"Tan Y.","year":"2014","unstructured":"Tan Y, Wang KY, Wang N, Li G, Liu D. BMC Biotechnol, Ectopic expression of human acidic fibroblast growth factor 1 in the medicinal plant, Salvia miltiorrhiza, accelerates the healing of burn wounds.,, 2014, 14,, 1-,","journal-title":"BMC Biotechnol"},{"key":"ref=50","doi-asserted-by":"crossref","first-page":"6551","DOI":"10.1158\/1078-0432.CCR-14-1337","volume":"20","author":"Capelletti M.","year":"2014","unstructured":"Capelletti M, Dodge ME, Ercan D. Clin Cancer Res, Identification of recurrent fgfr3-tacc3 fusion oncogenes from lung adenocarcinoma.,, 2014, 20,, 6551-6558,","journal-title":"Clin Cancer Res"},{"key":"ref=51","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1042\/CS20140100","volume":"127","author":"Coleman S.J.","year":"2014","unstructured":"Coleman SJ, Bruce C, Chioni A-M, Kocher HM, Grose RP. Clin Sci, The ins and outs of fibroblast growth factor receptor signalling.,, 2014, 127,, 217-231,","journal-title":"Clin Sci"},{"key":"ref=52","author":"Levy-Adam F.","unstructured":"Levy-Adam F, Ilan N, Vlodavsky I, , ,, , 2010: Elsevier., Tumorigenic and adhesive properties of heparanase. Seminars in cancer biology., ,-","journal-title":"Tumorigenic and adhesive properties of heparanase Seminars in cancer biology"},{"key":"ref=53","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1158\/1541-7786.MCR-12-0275","volume":"10","author":"Bohrer L.R.","year":"2012","unstructured":"Bohrer LR, Schwertfeger KL. Mol Cancer Res, Macrophages promote fibroblast growth factor receptor-driven tumor cell migration and invasion in a CXCR2-dependent manner.,, 2012, 10,, 1294-1305,","journal-title":"Mol Cancer Res"},{"key":"ref=54","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.cytogfr.2005.01.004","volume":"16","author":"Presta M.","year":"2005","unstructured":"Presta M, Dell\u2019Era P, Mitola S. Cytokine Growth Factor Rev, Fibroblast growth factor\/fibroblast growth factor receptor system in angiogenesis.,, 2005, 16,, 159-178,","journal-title":"Cytokine Growth Factor Rev"},{"key":"ref=55","doi-asserted-by":"crossref","first-page":"e57927","DOI":"10.1371\/journal.pone.0057927","volume":"8","author":"Mori S.","year":"2013","unstructured":"Mori S, Tran V, Nishikawa K. PLoS One, A dominant-negative FGF1 mutant (the R50E mutant) suppresses tumorigenesis and angiogenesis.,, 2013, 8,, e57927-,","journal-title":"PLoS One"},{"key":"ref=56","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1111\/j.1349-7006.2007.00432.x","volume":"98","author":"Tsunoda S.","year":"2007","unstructured":"Tsunoda S, Nakamura T, Sakurai H, Saiki I. Cancer Sci, Fibroblast growth factor\u20102\u2010induced host stroma reaction during initial tumor growth promotes progression of mouse melanoma via vascular endothelial growth factor A\u2010dependent neovascularization.,, 2007, 98,, 541-548,","journal-title":"Cancer Sci"},{"key":"ref=57","doi-asserted-by":"crossref","first-page":"2766","DOI":"10.1172\/JCI32479","volume":"117","author":"Nissen L.J.","year":"2007","unstructured":"Nissen LJ, Cao R, Hedlund E-M. J Clin Invest, Angiogenic factors FGF2 and PDGF-BB synergistically promote murine tumor neovascularization and metastasis.,, 2007, 117,, 2766-2777,","journal-title":"J Clin Invest"},{"key":"ref=58","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1038\/nm848","volume":"9","author":"Cao R.","year":"2003","unstructured":"Cao R, Br\u00e5kenhielm E, Pawliuk R. Nat Med, Angiogenic synergism, vascular stability and improvement of hind-limb ischemia by a combination of PDGF-BB and FGF-2.,, 2003, 9,, 604-613,","journal-title":"Nat Med"},{"key":"ref=59","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1006\/mthe.2002.0579","volume":"5","author":"Doukas J.","year":"2002","unstructured":"Doukas J, Blease K, Craig D. Mol Ther, Delivery of FGF genes to wound repair cells enhances arteriogenesis and myogenesis in skeletal muscle.,, 2002, 5,, 517-527,","journal-title":"Mol Ther"},{"key":"ref=60","doi-asserted-by":"crossref","first-page":"18066","DOI":"10.1074\/jbc.M801213200","volume":"283","author":"Mori S.","year":"2008","unstructured":"Mori S, Wu C-Y, Yamaji S. J Biol Chem, Direct binding of integrin \u03b1v\u03b23 to FGF1 plays a role in FGF1 signaling.,, 2008, 283,, 18066-18075,","journal-title":"J Biol Chem"},{"key":"ref=61","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1089\/lrb.2008.1007","volume":"6","author":"Cao Y.","year":"2008","unstructured":"Cao Y. Lymphat Res Biol, Why and how do tumors stimulate lymphangiogenesis?,, 2008, 6,, 145-148,","journal-title":"Lymphat Res Biol"},{"key":"ref=62","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1038\/nprot.2011.359","volume":"6","author":"Cao R.","year":"2011","unstructured":"Cao R, Lim S, Ji H. Nat Protoc, Mouse corneal lymphangiogenesis model.,, 2011, 6,, 817-826,","journal-title":"Nat Protoc"},{"key":"ref=63","doi-asserted-by":"crossref","first-page":"15894","DOI":"10.1073\/pnas.1208324109","volume":"109","author":"Cao R.","year":"2012","unstructured":"Cao R, Ji H, Feng N. Proc Natl Acad Sci, Collaborative interplay between FGF-2 and VEGF-C promotes lymphangiogenesis and metastasis.,, 2012, 109,, 15894-15899,","journal-title":"Proc Natl Acad Sci"},{"key":"ref=64","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1038\/nature10998","volume":"485","author":"Jonker J.W.","year":"2012","unstructured":"Jonker JW, Suh JM, Atkins AR. Nature, A PPAR [ggr]-FGF1 axis is required for adaptive adipose remodelling and metabolic homeostasis.,, 2012, 485,, 391-394,","journal-title":"Nature"},{"key":"ref=65","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1038\/nature13540","volume":"513","author":"Suh J.M.","year":"2014","unstructured":"Suh JM, Jonker JW, Ahmadian M. Nature, Endocrinization of FGF1 produces a neomorphic and potent insulin sensitizer.,, 2014, 513,, 436-439,","journal-title":"Nature"},{"key":"ref=66","doi-asserted-by":"crossref","first-page":"e0118931","DOI":"10.1371\/journal.pone.0118931","volume":"10","author":"Onuma Y.","year":"2015","unstructured":"Onuma Y, Higuchi K, Aiki Y. PLoS One, A Stable chimeric fibroblast growth factor (fgf) can successfully replace basic fgf in human pluripotent stem cell culture.,, 2015, 10,, e0118931-,","journal-title":"PLoS One"},{"key":"ref=67","doi-asserted-by":"crossref","first-page":"8751","DOI":"10.1074\/jbc.M209936200","volume":"278","author":"Facchiano A.","year":"2003","unstructured":"Facchiano A, Russo K, Facchiano AM. J Biol Chem, Identification of a novel domain of fibroblast growth factor 2 controlling its angiogenic properties.,, 2003, 278,, 8751-8760,","journal-title":"J Biol Chem"},{"key":"ref=68","doi-asserted-by":"crossref","first-page":"10571","DOI":"10.1007\/s13277-014-2356-4","volume":"35","author":"Fan L.","year":"2014","unstructured":"Fan L, Xie H, Chen L. Tumour Biol, A novel FGF2 antagonist peptide P8 with potent antiproliferation activity.,, 2014, 35,, 10571-10579,","journal-title":"Tumour Biol"},{"key":"ref=69","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/j.tips.2016.10.003","volume":"37","author":"Katoh M.","year":"2016","unstructured":"Katoh M. Trends Pharmacol Sci, Therapeutics targeting FGF signaling network in human diseases.,, 2016, 37,, 1081-1096,","journal-title":"Trends Pharmacol Sci"},{"key":"ref=70","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.lungcan.2013.10.004","volume":"83","author":"Preusser M.","year":"2014","unstructured":"Preusser M, Berghoff AS, Berger W. Lung Cancer, High rate of FGFR1 amplifications in brain metastases of squamous and non-squamous lung cancer.,, 2014, 83,, 83-89,","journal-title":"Lung Cancer"},{"key":"ref=71","doi-asserted-by":"crossref","first-page":"R24","DOI":"10.1186\/bcr3623","volume":"16","author":"Wendt M.K.","year":"2014","unstructured":"Wendt MK, Taylor MA, Schiemann BJ, Sossey-Alaoui K, Schiemann WP. Breast Cancer Res, Fibroblast growth factor receptor splice variants are stable markers of oncogenic transforming growth factor-beta1 signaling in metastatic breast cancers.,, 2014, 16,, R24-,","journal-title":"Breast Cancer Res"},{"key":"ref=72","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1111\/jcmm.12371","volume":"18","author":"Shi H.","year":"2014","unstructured":"Shi H, Fu C, Wang W. J Cell Mol Med, The FGF\u20101\u2010specific single\u2010chain antibody scFv1C9 effectively inhibits breast cancer tumour growth and metastasis.,, 2014, 18,, 2061-2070,","journal-title":"J Cell Mol Med"},{"key":"ref=73","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/sj.onc.1210623","volume":"27","author":"Desnoyers L.","year":"2008","unstructured":"Desnoyers L, Pai R, Ferrando R. Oncogene, Targeting FGF19 inhibits tumor growth in colon cancer xenograft and FGF19 transgenic hepatocellular carcinoma models.,, 2008, 27,, 85-97,","journal-title":"Oncogene"},{"key":"ref=74","doi-asserted-by":"crossref","first-page":"5750","DOI":"10.1158\/1078-0432.CCR-10-0531","volume":"16","author":"Zhao W-m.","year":"2010","unstructured":"Zhao W-m, Wang L, Park H. Clin Cancer Res, Monoclonal antibodies to fibroblast growth factor receptor 2 effectively inhibit growth of gastric tumor xenografts.,, 2010, 16,, 5750-5758,","journal-title":"Clin Cancer Res"},{"key":"ref=75","doi-asserted-by":"crossref","first-page":"4039","DOI":"10.1182\/blood-2005-10-4179","volume":"107","author":"Trudel S.","year":"2006","unstructured":"Trudel S, Stewart AK, Rom E. Blood, The inhibitory anti-FGFR3 antibody, PRO-001, is cytotoxic to t (4; 14) multiple myeloma cells.,, 2006, 107,, 4039-4046,","journal-title":"Blood"},{"key":"ref=76","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1002\/jbmr.275","volume":"26","author":"Aono Y.","year":"2011","unstructured":"Aono Y, Hasegawa H, Yamazaki Y. J Bone Miner Res, Anti\u2010FGF\u201023 neutralizing antibodies ameliorate muscle weakness and decreased spontaneous movement of Hyp mice.,, 2011, 26,, 803-810,","journal-title":"J Bone Miner Res"},{"key":"ref=77","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1172\/JCI38017","volume":"119","author":"Qing J.","year":"2009","unstructured":"Qing J, Du X, Chen Y. J Clin Invest, Antibody-based targeting of FGFR3 in bladder carcinoma and t (4; 14)-positive multiple myeloma in mice.,, 2009, 119,, 1216-1229,","journal-title":"J Clin Invest"},{"key":"ref=78","first-page":"20","volume":"10","author":"Matsuda Y.","year":"2014","unstructured":"Matsuda Y, Shinji S, Yoshimura H, Naito Z, Ishiwata T. Current Col Cancer Rep, Fibroblast growth factor receptor-2 IIIc as a novel molecular target in colorectal cancer.,, 2014, 10,, 20-26,","journal-title":"Current Col Cancer Rep"},{"key":"ref=79","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/j.tips.2016.10.003","volume":"37","author":"Katoh M.","year":"2016","unstructured":"Katoh M. Trends Pharmacol Sci, Therapeutics targeting fgf signaling network in human diseases.,, 2016, 37,, 1081-1096,","journal-title":"Trends Pharmacol Sci"},{"key":"ref=80","doi-asserted-by":"crossref","first-page":"E964","DOI":"10.1152\/ajpendo.00089.2006","volume":"292","author":"Sun H.D.","year":"2007","unstructured":"Sun HD, Malabunga M, Tonra JR. Am J Physiol Endocrinol Metab, Monoclonal antibody antagonists of hypothalamic FGFR1 cause potent but reversible hypophagia and weight loss in rodents and monkeys.,, 2007, 292,, E964-E76,","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"ref=81","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1128\/MMBR.67.4.657-685.2003","volume":"67","author":"Agrawal N.","year":"2003","unstructured":"Agrawal N, Dasaradhi P, Mohmmed A. Microbiol Mol Biol Rev, RNA interference: Biology, mechanism, and applications.,, 2003, 67,, 657-685,","journal-title":"Microbiol Mol Biol Rev"},{"key":"ref=82","first-page":"130","volume":"88","author":"Chen D-b.","year":"2013","unstructured":"Chen D-b, Wang W. Biol Reprod, Human placental microRNAs and preeclampsia.,, 2013, 88,, 130-,","journal-title":"Biol Reprod"},{"key":"ref=83","doi-asserted-by":"crossref","first-page":"275","DOI":"10.4161\/cbt.7.2.5574","volume":"7","author":"Katoh M.","year":"2008","unstructured":"Katoh M. Cancer Biol Ther, RNA technology targeted to the WNT signaling pathway.,, 2008, 7,, 275-277,","journal-title":"Cancer Biol Ther"},{"key":"ref=84","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1159\/000335472","volume":"81","author":"Cheng A-L.","year":"2012","unstructured":"Cheng A-L, Shen Y-C, Zhu AX. Oncol, Targeting fibroblast growth factor receptor signaling in hepatocellular carcinoma.,, 2012, 81,, 372-380,","journal-title":"Oncol"},{"key":"ref=85","doi-asserted-by":"crossref","first-page":"32490","DOI":"10.1074\/jbc.M113.496109","volume":"288","author":"Shah C.A.","year":"2013","unstructured":"Shah CA, Bei L, Wang H, Platanias LC, Eklund EA. J Biol Chem, The leukemia-associated Mll-Ell oncoprotein induces fibroblast growth factor 2 (Fgf2)-dependent cytokine hypersensitivity in myeloid progenitor cells.,, 2013, 288,, 32490-32505,","journal-title":"J Biol Chem"},{"key":"ref=86","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1158\/1078-0432.CCR-12-2736","volume":"19","author":"Zaid T.M.","year":"2013","unstructured":"Zaid TM, Yeung T-L, Thompson MS. Clin Cancer Res, Identification of FGFR4 as a potential therapeutic target for advanced-stage, high-grade serous ovarian cancer.,, 2013, 19,, 809-820,","journal-title":"Clin Cancer Res"},{"key":"ref=87","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.ijsu.2011.05.002","volume":"9","author":"Adas G.","year":"2011","unstructured":"Adas G, Percem A, Adas M. Int J Surg, VEGF-A and FGF gene therapy accelerate healing of ischemic colonic anastomoses (experimental study).,, 2011, 9,, 467-471,","journal-title":"Int J Surg"},{"key":"ref=88","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1113\/expphysiol.2005.030403","volume":"90","author":"Morishita R.","year":"2005","unstructured":"Morishita R, Aoki M, Ogihara T. Exp Physiol, Does gene therapy become pharmacotherapy?,, 2005, 90,, 307-313,","journal-title":"Exp Physiol"},{"key":"ref=89","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/sj.cgt.7700470","volume":"9","author":"Maruta F.","year":"2002","unstructured":"Maruta F, Parker AL, Fisher KD. Cancer Gene Ther, Identification of FGF receptor-binding peptides for cancer gene therapy.,, 2002, 9,, 543-552,","journal-title":"Cancer Gene Ther"},{"key":"ref=90","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1517\/13543784.2014.871259","volume":"23","author":"Sonpavde G.","year":"2014","unstructured":"Sonpavde G, Willey CD, Sudarshan S. Expert Opin Investig Drugs, Fibroblast growth factor receptors as therapeutic targets in clear-cell renal cell carcinoma.,, 2014, 23,, 305-315,","journal-title":"Expert Opin Investig Drugs"},{"key":"ref=91","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1159\/000342099","volume":"84","author":"Porta C.","year":"2012","unstructured":"Porta C, Paglino C, Imarisio I. Oncol, Changes in circulating pro-angiogenic cytokines, other than VEGF, before progression to sunitinib therapy in advanced renal cell carcinoma patients.,, 2012, 84,, 115-122,","journal-title":"Oncol"},{"key":"ref=92","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.biopha.2018.12.022","volume":"110","author":"Fallah A.","year":"2019","unstructured":"Fallah A, Sadeghinia A, Kahroba H. Biomed Pharmacother, Therapeutic targeting of angiogenesis molecular pathways in angiogenesis-dependent diseases.,, 2019, 110,, 775-785,","journal-title":"Biomed Pharmacother"},{"key":"ref=93","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1158\/0008-5472.CAN-11-3034","volume":"72","author":"Gavine P.R.","year":"2012","unstructured":"Gavine PR, Mooney L, Kilgour E. Cancer Res, AZD4547: An orally bioavailable, potent, and selective inhibitor of the fibroblast growth factor receptor tyrosine kinase family.,, 2012, 72,, 2045-2056,","journal-title":"Cancer Res"},{"key":"ref=94","doi-asserted-by":"crossref","first-page":"2244","DOI":"10.1093\/annonc\/mdu390","volume":"25","author":"Soria J-C.","year":"2014","unstructured":"Soria J-C, DeBraud F, Bahleda R. Ann Oncol, Phase I\/IIa study evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of lucitanib in advanced solid tumors.,, 2014, 25,, 2244-2251,","journal-title":"Ann Oncol"},{"key":"ref=95","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/s41571-018-0115-y","volume":"16","author":"Katoh M.","year":"2019","unstructured":"Katoh M. Nat Rev Clin Oncol, Fibroblast growth factor receptors as treatment targets in clinical oncology.,, 2019, 16,, 105-122,","journal-title":"Nat Rev Clin Oncol"},{"key":"ref=96","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1021\/acschembio.5b00014","volume":"10","author":"Sohl C.D.","year":"2015","unstructured":"Sohl CD, Ryan MR, Luo B, Frey KM, Anderson KS. ACS Chem Biol, Illuminating the molecular mechanisms of tyrosine kinase inhibitor resistance for the fgfr1 gatekeeper mutation: The achilles\u2019 heel of targeted therapy.,, 2015, 10,, 1319-1329,","journal-title":"ACS Chem Biol"},{"key":"ref=97","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.nbd.2011.08.004","volume":"45","author":"Zhou Y-X.","year":"2012","unstructured":"Zhou Y-X, Pannu R, Le TQ, Armstrong RC. Neurobiol Dis, Fibroblast growth factor 1 (FGFR1) modulation regulates repair capacity of oligodendrocyte progenitor cells following chronic demyelination.,, 2012, 45,, 196-205,","journal-title":"Neurobiol Dis"},{"key":"ref=98","doi-asserted-by":"crossref","first-page":"25571","DOI":"10.1074\/jbc.M501920200","volume":"280","author":"Vargas M.R.","year":"2005","unstructured":"Vargas MR, Pehar M, Cassina P. J Biol Chem, Fibroblast growth factor-1 induces heme oxygenase-1 via nuclear factor erythroid 2-related factor 2 (nrf2) in spinal cord astrocytes consequences for motor neuron survival.,, 2005, 280,, 25571-25579,","journal-title":"J Biol Chem"},{"key":"ref=99","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40478-014-0168-9","volume":"2","author":"Mohan H.","year":"2014","unstructured":"Mohan H, Friese A, Albrecht S. Acta Neuropathol Commun, Transcript profiling of different types of multiple sclerosis lesions yields FGF1 as a promoter of remyelination.,, 2014, 2,, 1-,","journal-title":"Acta Neuropathol Commun"},{"key":"ref=100","doi-asserted-by":"crossref","first-page":"e21615","DOI":"10.5812\/ircmj.21615","volume":"18","author":"Soleyman M.R.","year":"2016","unstructured":"Soleyman MR, Khalili M, Khansarinejad B, Baazm M. Iran Red Crescent Med J, High-level expression and purification of active human FGF-2 in Escherichia coli by codon and culture condition optimization.,, 2016, 18,, e21615-,","journal-title":"Iran Red Crescent Med J"},{"key":"ref=101","doi-asserted-by":"crossref","first-page":"553","DOI":"10.2174\/1381612033391379","volume":"9","author":"Presta M.","year":"2003","unstructured":"Presta M, Leali D, Stabile H. Curr Pharm Des, Heparin derivatives as angiogenesis inhibitors.,, 2003, 9,, 553-566,","journal-title":"Curr Pharm Des"},{"key":"ref=102","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1097\/MOH.0b013e3282f97d98","volume":"15","author":"Murakami M.","year":"2008","unstructured":"Murakami M, Simons M. Curr Opin Hematol, Fibroblast growth factor regulation of neovascularization.,, 2008, 15,, 215-,","journal-title":"Curr Opin Hematol"},{"key":"ref=103","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1038\/nrc2458","volume":"8","author":"Zetter B.R.","year":"2008","unstructured":"Zetter BR. Nat Rev Cancer, The scientific contributions of M. Judah Folkman to cancer research.,, 2008, 8,, 647-654,","journal-title":"Nat Rev Cancer"},{"key":"ref=104","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1111\/j.1365-2133.2006.07724.x","volume":"156","author":"Kurschat P.","year":"2007","unstructured":"Kurschat P, Eming S, Nashan D, Krieg T, Mauch C. Br J Dermatol, Early increase in serum levels of the angiogenesis\u2010inhibitor endostatin and of basic fibroblast growth factor in melanoma patients during disease progression.,, 2007, 156,, 653-658,","journal-title":"Br J Dermatol"},{"key":"ref=105","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.canlet.2015.01.012","volume":"359","author":"Xiao L.","year":"2015","unstructured":"Xiao L, Yang S, Hao J. Cancer Lett, Endostar attenuates melanoma tumor growth via its interruption of b-FGF mediated angiogenesis.,, 2015, 359,, 148-154,","journal-title":"Cancer Lett"},{"key":"ref=106","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/edt.12071","volume":"30","author":"Sonmez A.B.","year":"2014","unstructured":"Sonmez AB, Castelnuovo J. Dent Traumatol, Applications of basic fibroblastic growth factor (FGF\u20102, bFGF) in dentistry.,, 2014, 30,, 107-111,","journal-title":"Dent Traumatol"},{"key":"ref=107","first-page":"318","volume":"8","author":"Hatch N.","year":"2008","unstructured":"Hatch N, Franceschi R. J Musculoskelet Neuronal Interact, FGF2 induced expression of the pyrophosphate generating enzyme, PC-1, is mediated by Runx2 and Msx2.,, 2008, 8,, 318-,","journal-title":"J Musculoskelet Neuronal Interact"},{"key":"ref=108","author":"Kitamura C","year":"","unstructured":"Kitamura C, Nishihara T, Terashita M, Tabata Y, Washio A. , , Local regeneration of dentin-pulp complex using controlled release of FGF-2 and naturally derived sponge-like scaffolds. Int J Dentistry 2011; 2012.,"},{"key":"ref=109","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1111\/edt.12141","volume":"31","author":"Tuna E.B.","year":"2015","unstructured":"Tuna EB, Arai K, Tekkesin MS. Dent Traumatol, Effect of fibroblast growth factor and enamel matrix derivative treatment on root resorption after delayed replantation.,, 2015, 31,, 49-56,","journal-title":"Dent Traumatol"},{"key":"ref=110","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1111\/odi.12089","volume":"20","author":"Kim J.","year":"2014","unstructured":"Kim J, Park JC, Kim SH. Oral Dis, Treatment of FGF\u20102 on stem cells from inflamed dental pulp tissue from human deciduous teeth.,, 2014, 20,, 191-204,","journal-title":"Oral Dis"},{"key":"ref=111","doi-asserted-by":"crossref","first-page":"e108031","DOI":"10.1371\/journal.pone.0108031","volume":"9","author":"Wolf W.A.","year":"2014","unstructured":"Wolf WA, Martin JL, Kartje GL, Farrer RG. PLoS One, Evidence for fibroblast growth factor-2 as a mediator of amphetamine-enhanced motor improvement following stroke.,, 2014, 9,, e108031-,","journal-title":"PLoS One"},{"key":"ref=112","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1016\/j.neuropharm.2008.07.014","volume":"55","author":"Bachis A.","year":"2008","unstructured":"Bachis A, Mallei A, Cruz MI, Wellstein A, Mocchetti I. Neuropharmacology, Chronic antidepressant treatments increase basic fibroblast growth factor and fibroblast growth factor-binding protein in neurons.,, 2008, 55,, 1114-1120,","journal-title":"Neuropharmacology"},{"key":"ref=113","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1111\/odi.12002","volume":"19","author":"Catalfamo D.L.","year":"2013","unstructured":"Catalfamo DL, Britten TM, Storch DI. Oral Dis, Hyperglycemia induced and intrinsic alterations in type 2 diabetes\u2010derived osteoclast function.,, 2013, 19,, 303-312,","journal-title":"Oral Dis"},{"key":"ref=114","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1016\/j.jacc.2004.11.067","volume":"45","author":"Fadini G.P.","year":"2005","unstructured":"Fadini GP, Miorin M, Facco M. J Am Coll Cardiol, Circulating endothelial progenitor cells are reduced in peripheral vascular complications of type 2 diabetes mellitus.,, 2005, 45,, 1449-1457,","journal-title":"J Am Coll Cardiol"},{"key":"ref=115","doi-asserted-by":"crossref","first-page":"e0118823","DOI":"10.1371\/journal.pone.0118823","volume":"10","author":"Wallner C.","year":"2015","unstructured":"Wallner C, Schira J, Wagner JM. PLoS One, Application of VEGFA and FGF-9 enhances angiogenesis, osteogenesis and bone remodeling in type 2 diabetic long bone regeneration.,, 2015, 10,, e0118823-,","journal-title":"PLoS One"},{"key":"ref=116","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.mce.2003.12.017","volume":"218","author":"Asaki T.","year":"2004","unstructured":"Asaki T, Konishi M, Miyake A. Mol Cell Endocrinol, Roles of fibroblast growth factor 10 (Fgf10) in adipogenesis in vivo.,, 2004, 218,, 119-128,","journal-title":"Mol Cell Endocrinol"},{"key":"ref=117","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.mce.2006.01.010","volume":"249","author":"Konishi M.","year":"2006","unstructured":"Konishi M, Asaki T, Koike N. Mol Cell Endocrinol, Role of Fgf10 in cell proliferation in white adipose tissue.,, 2006, 249,, 71-77,","journal-title":"Mol Cell Endocrinol"},{"key":"ref=118","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1210\/jc.2002-021062","volume":"88","author":"Taniguchi F.","year":"2003","unstructured":"Taniguchi F, Harada T, Sakamoto Y. J Clin Endocrinol Metab, Activation of mitogen-activated protein kinase pathway by keratinocyte growth factor or fibroblast growth factor-10 promotes cell proliferation in human endometrial carcinoma cells.,, 2003, 88,, 773-780,","journal-title":"J Clin Endocrinol Metab"},{"key":"ref=119","doi-asserted-by":"crossref","first-page":"18","DOI":"10.3389\/fendo.2014.00107","volume":"5","author":"Itoh N.","year":"2014","unstructured":"Itoh N, Ohta H. Front Endocrinol, Roles of FGFs as adipokines in adipose tissue development, remodeling, and metabolism.,, 2014, 5,, 18-,","journal-title":"Front Endocrinol"},{"key":"ref=120","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.bbrc.2014.11.063","volume":"456","author":"Li Y-H.","year":"2015","unstructured":"Li Y-H, Yang L-Y, Chen W, Li Y-K, Yuan H-B. Biochem Biophys Res Commun, Fibroblast growth factor 10 protects neuron against oxygen-glucose deprivation injury through inducing heme oxygenase-1.,, 2015, 456,, 225-231,","journal-title":"Biochem Biophys Res Commun"},{"key":"ref=121","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.det.2012.08.002","volume":"31","author":"Patel M.","year":"2013","unstructured":"Patel M, Harrison S, Sinclair R. Dermatol Clin, Drugs and hair loss.,, 2013, 31,, 67-73,","journal-title":"Dermatol Clin"},{"key":"ref=122","doi-asserted-by":"crossref","first-page":"25823","DOI":"10.1074\/jbc.M110.198267","volume":"286","author":"Nakayama F.","year":"2011","unstructured":"Nakayama F, Yasuda T, Umeda S. J Biol Chem, Fibroblast growth factor-12 (FGF12) translocation into intestinal epithelial cells is dependent on a novel cell-penetrating peptide domain involvement of internalization in the in vivo role of exogenous FGF12.,, 2011, 286,, 25823-25834,","journal-title":"J Biol Chem"},{"key":"ref=123","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.ijrobp.2013.10.035","volume":"88","author":"Nakayama F.","year":"2014","unstructured":"Nakayama F, Umeda S, Yasuda T. Int J Radiat Oncol Biol Phys, Cellular internalization of fibroblast growth factor-12 exerts radioprotective effects on intestinal radiation damage independently of FGFR signaling.,, 2014, 88,, 377-384,","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"ref=124","author":"Jiang X","year":"","unstructured":"Jiang X, Skibba M, Zhang C. , , The roles of fibroblast growth factors in the testicular development and tumor. J Diabetes Res 2013; 2013.,"},{"key":"ref=125","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1517\/14728222.2014.997711","volume":"19","author":"Liu W-Y.","year":"2015","unstructured":"Liu W-Y, Xie D-M, Zhu G-Q. Expert Opin Ther Targets, Targeting fibroblast growth factor 19 in liver disease: A potential biomarker and therapeutic target.,, 2015, 19,, 675-685,","journal-title":"Expert Opin Ther Targets"},{"key":"ref=126","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1038\/nrgastro.2014.32","volume":"11","author":"Walters J.R.","year":"2014","unstructured":"Walters JR. Nat Rev Gastroenterol Hepatol, Bile acid diarrhoea and FGF19: New views on diagnosis, pathogenesis and therapy.,, 2014, 11,, 426-434,","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"ref=127","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/nrd.2015.9","volume":"15","author":"Degirolamo C.","year":"2015","unstructured":"Degirolamo C, Sabb\u00e0 C, Moschetta A. Nat Rev Drug Discov, Therapeutic potential of the endocrine fibroblast growth factors FGF19, FGF21 and FGF23.,, 2015, 15,, 51-,","journal-title":"Nat Rev Drug Discov"},{"key":"ref=128","doi-asserted-by":"crossref","first-page":"G440","DOI":"10.1152\/ajpgi.00322.2009","volume":"298","author":"Schreuder T.C.","year":"2010","unstructured":"Schreuder TC, Marsman HA, Lenicek M. Am J Physiol Gastrointest Liver Physiol, The hepatic response to FGF19 is impaired in patients with nonalcoholic fatty liver disease and insulin resistance.,, 2010, 298,, G440-G5,","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"ref=129","doi-asserted-by":"crossref","first-page":"e67160","DOI":"10.1371\/journal.pone.0067160","volume":"8","author":"Alisi A.","year":"2013","unstructured":"Alisi A, Ceccarelli S, Panera N. PLoS One, Association between serum atypical fibroblast growth factors 21 and 19 and pediatric nonalcoholic fatty liver disease.,, 2013, 8,, e67160-,","journal-title":"PLoS One"},{"key":"ref=130","doi-asserted-by":"crossref","first-page":"16137","DOI":"10.1073\/pnas.1205951109","volume":"109","author":"Fu T.","year":"2012","unstructured":"Fu T, Choi S-E, Kim D-H. Proc Natl Acad Sci, Aberrantly elevated microRNA-34a in obesity attenuates hepatic responses to FGF19 by targeting a membrane coreceptor \u03b2-Klotho.,, 2012, 109,, 16137-16142,","journal-title":"Proc Natl Acad Sci"},{"key":"ref=131","first-page":"bgu151","author":"Gauglhofer C.","year":"2014","unstructured":"Gauglhofer C, Paur J, Schrottmaier WC. Carcinogenesis, Fibroblast growth factor receptor 4: A putative key driver for the aggressive phenotype of hepatocellular carcinoma.,, 2014, 109,, bgu151-,","journal-title":"Carcinogenesis"},{"key":"ref=132","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1086\/421052","volume":"74","author":"Van Der Walt J.M.","year":"2004","unstructured":"Van Der Walt JM, Noureddine MA, Kittappa R. Am J Hum Genet, Fibroblast growth factor 20 polymorphisms and haplotypes strongly influence risk of Parkinson disease.,, 2004, 74,, 1121-1127,","journal-title":"Am J Hum Genet"},{"key":"ref=133","doi-asserted-by":"crossref","first-page":"e59966","DOI":"10.1371\/journal.pone.0059966","volume":"8","author":"Shi H-X.","year":"2013","unstructured":"Shi H-X, Lin C, Lin B-B. PLoS One, The anti-scar effects of basic fibroblast growth factor on the wound repair in vitro and in vivo.,, 2013, 8,, e59966-,","journal-title":"PLoS One"},{"key":"ref=134","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.diabres.2015.02.032","volume":"108","author":"Liu J-J.","year":"2015","unstructured":"Liu J-J, Foo JP, Liu S, Lim SC. Diabetes Res Clin Pract, The role of fibroblast growth factor 21 in diabetes and its complications: A review from clinical perspective.,, 2015, 108,, 382-389,","journal-title":"Diabetes Res Clin Pract"},{"key":"ref=135","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1172\/JCI23606","volume":"115","author":"Kharitonenkov A.","year":"2005","unstructured":"Kharitonenkov A, Shiyanova TL, Koester A. J Clin Invest, FGF-21 as a novel metabolic regulator.,, 2005, 115,, 1627-1635,","journal-title":"J Clin Invest"},{"key":"ref=136","doi-asserted-by":"crossref","first-page":"9777","DOI":"10.1074\/jbc.M312392200","volume":"279","author":"Tohyama O.","year":"2004","unstructured":"Tohyama O, Imura A, Iwano A. J Biol Chem, Klotho is a novel \u03b2-glucuronidase capable of hydrolyzing steroid \u03b2-glucuronides.,, 2004, 279,, 9777-9784,","journal-title":"J Biol Chem"},{"key":"ref=137","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1002\/jbmr.65","volume":"25","author":"Tsuji K.","year":"2010","unstructured":"Tsuji K, Maeda T, Kawane T, Matsunuma A, Horiuchi N. J Bone Miner Res, Leptin stimulates fibroblast growth factor 23 expression in bone and suppresses renal 1\u03b1, 25\u2010dihydroxyvitamin D3 synthesis in leptin\u2010deficient ob\/ob Mice.,, 2010, 25,, 1711-1723,","journal-title":"J Bone Miner Res"},{"key":"ref=138","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1359\/JBMR.0301264","volume":"19","author":"Shimada T.","year":"2004","unstructured":"Shimada T, Hasegawa H, Yamazaki Y. J Bone Miner Res, FGF\u201023 is a potent regulator of vitamin D metabolism and phosphate homeostasis.,, 2004, 19,, 429-435,","journal-title":"J Bone Miner Res"},{"key":"ref=139","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1677\/JOE-07-0267","volume":"195","author":"Krajisnik T.","year":"2007","unstructured":"Krajisnik T, Bj\u00f6rklund P, Marsell R. J Endocrinol, Fibroblast growth factor-23 regulates parathyroid hormone and 1\u03b1-hydroxylase expression in cultured bovine parathyroid cells.,, 2007, 195,, 125-131,","journal-title":"J Endocrinol"},{"key":"ref=140","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1172\/JCI200419081","volume":"113","author":"Shimada T.","year":"2004","unstructured":"Shimada T, Kakitani M, Yamazaki Y. J Clin Invest, Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism.,, 2004, 113,, 561-568,","journal-title":"J Clin Invest"},{"key":"ref=141","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000365787","volume":"128","author":"Nitta K.","year":"2014","unstructured":"Nitta K, Nagano N, Tsuchiya K. Nephron Clin Pract, Fibroblast growth factor 23\/klotho axis in chronic kidney disease.,, 2014, 128,, 1-10,","journal-title":"Nephron Clin Pract"},{"key":"ref=142","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1038\/ki.2011.47","volume":"79","author":"Isakova T.","year":"2011","unstructured":"Isakova T, Wahl P, Vargas GS. Kidney Int, Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease.,, 2011, 79,, 1370-1378,","journal-title":"Kidney Int"},{"key":"ref=143","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1093\/ndt\/gfm672","volume":"23","author":"Marsell R.","year":"2008","unstructured":"Marsell R, Krajisnik T, G\u00f6ransson H. Nephrol Dial Transplant, Gene expression analysis of kidneys from transgenic mice expressing fibroblast growth factor-23.,, 2008, 23,, 827-833,","journal-title":"Nephrol Dial Transplant"},{"key":"ref=144","first-page":"e201284188","author":"Andrukhova O.","year":"2014","unstructured":"Andrukhova O, Smorodchenko A, Egerbacher M. The EMBO J, FGF23 promotes renal calcium reabsorption through the TRPV5 channel.,, 2014, 23,, e201284188-,","journal-title":"The EMBO J"},{"key":"ref=145","first-page":"e201303716","author":"Andrukhova O.","year":"2014","unstructured":"Andrukhova O, Slavic S, Smorodchenko A. EMBO Mol Med, FGF23 regulates renal sodium handling and blood pressure.,, 2014, 23,, e201303716-,","journal-title":"EMBO Mol Med"},{"key":"ref=146","doi-asserted-by":"crossref","first-page":"3072","DOI":"10.1093\/ndt\/gfs259","volume":"27","author":"Heine G.H.","year":"2012","unstructured":"Heine GH, Seiler S, Fliser D. Nephrol Dial Transplant, FGF-23: The rise of a novel cardiovascular risk marker in CKD.,, 2012, 27,, 3072-3081,","journal-title":"Nephrol Dial Transplant"},{"key":"ref=147","doi-asserted-by":"crossref","first-page":"15694","DOI":"10.1074\/jbc.M601252200","volume":"281","author":"Zhang X.","year":"2006","unstructured":"Zhang X, Ibrahimi OA, Olsen SK. J Biol Chem, Receptor specificity of the fibroblast growth factor family The complete mammalian fgf family.,, 2006, 281,, 15694-15700,","journal-title":"J Biol Chem"},{"key":"ref=148","doi-asserted-by":"crossref","first-page":"E284","DOI":"10.1097\/01.BRS.0000131217.61390.2C","volume":"29","author":"Cheng H.","year":"2004","unstructured":"Cheng H, Liao K-K, Liao S-F, Chuang T-Y, Shih Y-H. Spine, Spinal cord repair with acidic fibroblast growth factor as a treatment for a patient with chronic paraplegia.,, 2004, 29,, E284-E8,","journal-title":"Spine"},{"key":"ref=149","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1016\/j.jacc.2007.06.010","volume":"50","author":"Henry T.D.","year":"2007","unstructured":"Henry TD, Grines CL, Watkins MW. J Am Coll Cardiol, Effects of Ad5FGF-4 in patients with angina: An analysis of pooled data from the AGENT-3 and AGENT-4 trials.,, 2007, 50,, 1038-1046,","journal-title":"J Am Coll Cardiol"},{"key":"ref=150","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1016\/0092-8674(94)90276-3","volume":"78","author":"H\u00e9bert J.M.","year":"1994","unstructured":"H\u00e9bert JM, Rosenquist T, G\u00f6tz J, Martin GR. Cell, FGF5 as a regulator of the hair growth cycle: Evidence from targeted and spontaneous mutations.,, 1994, 78,, 1017-1025,","journal-title":"Cell"},{"key":"ref=151","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.copbio.2003.08.003","volume":"14","author":"Steiling H.","year":"2003","unstructured":"Steiling H, Werner S. Curr Opin Biotechnol, Fibroblast growth factors: Key players in epithelial morphogenesis, repair and cytoprotection.,, 2003, 14,, 533-537,","journal-title":"Curr Opin Biotechnol"},{"key":"ref=152","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.joca.2005.03.003","volume":"13","author":"Moore E.","year":"2005","unstructured":"Moore E, Bendele A, Thompson D. Osteoarthritis Cartilage, Fibroblast growth factor-18 stimulates chondrogenesis and cartilage repair in a rat model of injury-induced osteoarthritis.,, 2005, 13,, 623-631,","journal-title":"Osteoarthritis Cartilage"},{"key":"ref=153","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1172\/JCI21137","volume":"115","author":"Takagi Y.","year":"2005","unstructured":"Takagi Y, Takahashi J, Saiki H. J Clin Invest, Dopaminergic neurons generated from monkey embryonic stem cells function in a Parkinson primate model.,, 2005, 115,, 102-109,","journal-title":"J Clin Invest"},{"key":"ref=154","doi-asserted-by":"crossref","first-page":"2470","DOI":"10.2337\/db05-1435","volume":"55","author":"Wente W.","year":"2006","unstructured":"Wente W, Efanov AM, Brenner M. Diabetes, Fibroblast growth factor-21 improves pancreatic \u03b2-cell function and survival by activation of extracellular signal-regulated kinase 1\/2 and Akt signaling pathways.,, 2006, 55,, 2470-2478,","journal-title":"Diabetes"},{"key":"ref=155","author":"Aono Y","year":"","unstructured":""},{"key":"ref=156","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1159\/000370118","volume":"88","author":"Tsimafeyeu I.","year":"2015","unstructured":"Tsimafeyeu I, Bratslavsky G. Oncol, Fibroblast growth factor receptor 1 as a target for the therapy of renal cell carcinoma.,, 2015, 88,, 321-331,","journal-title":"Oncol"},{"key":"ref=157","author":"Inokuchi M","year":"2015","unstructured":"Inokuchi M, Fujimori Y, Otsuki S. Gastroenterology Res Practice 2015;, Therapeutic targeting of fibroblast growth factor receptors in gastric cancer., , 2015","journal-title":"Gastroenterology Res Practice 2015;"},{"key":"ref=158","doi-asserted-by":"crossref","first-page":"3354","DOI":"10.1245\/s10434-010-1323-6","volume":"17","author":"Ye Y.","year":"2010","unstructured":"Ye Y, Shi Y, Zhou Y. Ann Surg Oncol, The fibroblast growth factor receptor-4 Arg388 allele is associated with gastric cancer progression.,, 2010, 17,, 3354-3361,","journal-title":"Ann Surg Oncol"},{"key":"ref=159","doi-asserted-by":"crossref","first-page":"4466","DOI":"10.1021\/jm900431g","volume":"52","author":"Roth G.J.","year":"2009","unstructured":"Roth GJ, Heckel A, Colbatzky F. J Med Chem, Design, synthesis, and evaluation of indolinones as triple angiokinase inhibitors and the discovery of a highly specific 6-methoxycarbonyl-substituted indolinone (BIBF 1120).,, 2009, 52,, 4466-4480,","journal-title":"J Med Chem"},{"key":"ref=160","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.canlet.2011.03.015","volume":"307","author":"Qiu H.","year":"2011","unstructured":"Qiu H, Yashiro M, Zhang X, Miwa A, Hirakawa KA. Cancer Lett, FGFR2 inhibitor, Ki23057, enhances the chemosensitivity of drug-resistant gastric cancer cells.,, 2011, 307,, 47-52,","journal-title":"Cancer Lett"},{"key":"ref=161","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1634\/theoncologist.2011-S2-14","volume":"16","author":"Hutson T.E.","year":"2011","unstructured":"Hutson TE. Oncologist, Targeted therapies for the treatment of metastatic renal cell carcinoma: Clinical evidence.,, 2011, 16,, 14-22,","journal-title":"Oncologist"},{"key":"ref=162","author":"Sherman S.","year":"","unstructured":"Sherman S, Jarzab B, Cabanillas M. , , -,"},{"key":"ref=163","doi-asserted-by":"crossref","first-page":"C469","DOI":"10.1152\/ajpcell.00452.2010","volume":"301","author":"Lin N.","year":"2011","unstructured":"Lin N, Chen S, Pan W. Am J Physiol Cell Physiol, NP603, a novel and potent inhibitor of FGFR1 tyrosine kinase, inhibits hepatic stellate cell proliferation and ameliorates hepatic fibrosis in rats.,, 2011, 301,, C469-C77,","journal-title":"Am J Physiol Cell Physiol"},{"key":"ref=164","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1002\/ijc.25864","volume":"129","author":"Wilhelm S.M.","year":"2011","unstructured":"Wilhelm SM, Dumas J, Adnane L. Int J Cancer, Regorafenib (BAY 73\u20104506): A new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity.,, 2011, 129,, 245-255,","journal-title":"Int J Cancer"},{"key":"ref=165","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.ajhg.2007.09.021","volume":"82","author":"Wang G.","year":"2008","unstructured":"Wang G, van der Walt JM, Mayhew G. Am J Hum Genet, Variation in the miRNA-433 binding site of FGF20 confers risk for Parkinson disease by overexpression of \u03b1-synuclein.,, 2008, 82,, 283-289,","journal-title":"Am J Hum Genet"},{"key":"ref=166","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1038\/jid.2011.55","volume":"131","author":"Xu N.","year":"2011","unstructured":"Xu N, Brodin P, Wei T. J Invest Dermatol, MiR-125b, a microRNA downregulated in psoriasis, modulates keratinocyte proliferation by targeting FGFR2.,, 2011, 131,, 1521-1529,","journal-title":"J Invest Dermatol"},{"key":"ref=167","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1074\/jbc.M110.170852","volume":"286","author":"Tsuchiya S.","year":"2011","unstructured":"Tsuchiya S, Fujiwara T, Sato F. J Biol Chem, MicroRNA-210 regulates cancer cell proliferation through targeting fibroblast growth factor receptor-like 1 (FGFRL1).,, 2011, 286,, 420-428,","journal-title":"J Biol Chem"},{"key":"ref=168","first-page":"43","volume":"1","author":"Coleman S.J.","year":"2014","unstructured":"Coleman SJ. J Hepatocell Carcinoma, Fibroblast growth factor family as a potential target in the treatment of hepatocellular carcinoma.,, 2014, 1,, 43-54,","journal-title":"J Hepatocell Carcinoma"},{"key":"ref=169","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.3892\/mmr.2014.2792","volume":"11","author":"Wu D.","year":"2015","unstructured":"Wu D, Zhou Y, Pan H, Qu P, Zhou J. Mol Med Rep, MicroRNA-99a inhibits cell proliferation, colony formation ability, migration and invasion by targeting fibroblast growth factor receptor 3 in prostate cancer.,, 2015, 11,, 1469-1475,","journal-title":"Mol Med Rep"},{"key":"ref=170","doi-asserted-by":"crossref","first-page":"2595","DOI":"10.1161\/ATVBAHA.111.236521","volume":"31","author":"Chamorro-Jorganes A.","year":"2011","unstructured":"Chamorro-Jorganes A, Araldi E, Penalva LO. Arterioscler Thromb Vasc Biol, MicroRNA-16 and microRNA-424 regulate cell-autonomous angiogenic functions in endothelial cells via targeting vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1.,, 2011, 31,, 2595-2606,","journal-title":"Arterioscler Thromb Vasc Biol"}],"container-title":["Current Drug Targets"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/eurekaselect.com\/article\/download\/168947","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,10]],"date-time":"2022-09-10T10:49:05Z","timestamp":1662806945000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.eurekaselect.com\/168947\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,10]]},"references-count":170,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2019,5,10]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1389450120666190112145409","relation":{},"ISSN":["1389-4501"],"issn-type":[{"value":"1389-4501","type":"print"}],"subject":[],"published":{"date-parts":[[2019,5,10]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2018-08-21","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-01-01","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-01-02","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-05-10","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}